

## **IDMA 51<sup>st</sup> Annual Day Celebrations 2013 – A Report**

The IDMA 51<sup>st</sup> Annual Day Celebrations 2013 was held at The Lalit, Mumbai. Earlier, the 51<sup>st</sup> Annual General Meeting (AGM) was held at the same venue. The Annual Day Celebrations commenced with the ceremonial lighting of the lamp by the President Mr Manish U Doshi, accompanied by Mr Daara B Patel, Secretary General, the eminent Speakers - Mr V G Somani, Mr Amit Backliwal and Mr. Sriram Shrinivasan etc. About 200 members, invitees and Award winners participated.

The President Mr Doshi welcomed all the participants to the Celebrations. Addressing the gathering, he said that when he took office last year, he had assumed that “we will need to be on our guard from foreign vested interests who have been trying their utmost to derail what the Indian Pharma Industry has achieved – as the global supplier of affordable quality generic drugs. We realized very soon that, the pressures being applied, and questions being raised, were within the country by our own people. Although there have been many changes, we have been able to some extent withstand the onslaught, some of which may determine the course of the growth of the Indian Pharma Industry globally.”

Excerpts from his address are reproduced below:

*“We have come a long way in the past five decades and it is due to the combined efforts of our past Presidents, office bearers, State Boards, and the General Membership that we are today the apex body of Pharmaceutical manufacturers.*

*The successful completion of 50 years of service to the nation fills us with a sense of awe and satisfaction. Our founding Members, when they set up the Association,*

*would not have visualized such impressive growth of the Association that led to the spectacular growth of the Indian Pharmaceutical Industry, from being basically importers to becoming the largest suppliers of safe and affordable quality generic medicines in the world, with the befitting recognition as the Pharmacy of the World!*

*The year was unique and saw many firsts in your Association’s endeavours to discuss and work out solutions with the Government for the manufacturing and other related activities of Members, as also our active initiatives that brought your Association to national focus and goodwill. Due to our collective efforts in interactive meetings and effective recommendations to the government, we managed to get many issues resolved in your favour. A few are still under discussion and I will touch upon some of the important ones.*

### **National Pharmaceutical Pricing Policy 2012:**

*After many years of deliberations, the much awaited Pharmaceutical Policy was at last notified by the Government. The National Pharmaceutical Pricing Policy 2012 (NPPP 2012), as recommended by the Department of Pharmaceuticals, covers three key principles - essentiality of drugs, control only on formulations and market based pricing. The shift from cost based pricing to market based has been long overdue, as it has been stunting the industry’s growth and forcing manufacturers to discontinue production of some controlled drugs, as it is proving highly unviable. I will not go into too much detail, as the Policy is already in public domain, but it was high time that the Government realized that the various Drug Policies all these years were broadly based on the principle of putting a ceiling on prices of essential drugs on a 'lowest*

common denominator' basis. The Indian economy is today largely market-driven with prices determined by market conditions and market forces. None truer than the Indian Pharma Industry which has matured and has a number of manufacturers with intense competition in the market for almost every medicine, ensuring their continued availability and keeping prices in check. A paradigm shift from cost based pricing to market based pricing was thus long overdue, to ensure continuity in production and availability of controlled products. Patented drugs are however, in a different category as monopoly products and need some ceiling/control on prices.

The Pharma Industry is probably the only industry, where not only the input costs are controlled, but also the margins! Experience has also clearly proven that cost-based price controls are not in public interest.

The Government has now realized that keeping prices under strict control and artificially very low is neither going to benefit the patients, nor the industry. India is globally the 3<sup>rd</sup> largest producer of medicines by volume yet 14<sup>th</sup> in terms of value, due to the fact that our safe, efficacious and affordable medicines are also the lowest priced in the world!

Though there are a few clauses that need to be relooked, such as the pricing formula, overall, the Policy is fairly well balanced with availability and affordability being taken care of by ensuring that there is control on essential medicines, at the same time allowing market forces to ensure that prices are affordable. It is a very rational attempt at achieving a fine balance between reasonable prices, uninterrupted availability, administrative feasibility and future growth & investment.

The Pharma industry needs to be provided some returns to invest in NDDS, newer and better therapies and drugs; otherwise patients will not benefit as they will not have access to the same. The National Pharma Pricing Policy, as presently notified, appears to recognise this aspect. We sincerely pray that the Supreme Court, which may be delivering its verdict on 15 January 2013, also recognizes this pertinent point. Let us all await the day the Pharma Policy becomes a reality!

### **Barcoding for Pharma Export Packs:**

*Our efforts seeking an amicable solution to the contentious issue of barcoding for Pharma exports reached a stalemate, with the Madras High Court dismissing our plea for intervention against the implementation of barcoding.*

*Barcoding and serialization, as a solution to trace and track to be implemented on tertiary, secondary and primary packs, is still not practiced anywhere in the world, due to the almost impossible nature of the requirements. In good faith, the industry has agreed to incorporate barcodes on tertiary packs. The Indian Parliamentary Standing Committee on Health and Family Welfare in its 59<sup>th</sup> Report, presented to Parliament on 8<sup>th</sup> May 2012 records, and I quote **“Taking advantage of the confusion created by MNCs over fake and counterfeits, the so-called anti-counterfeit solution providers that sell barcode and other technologies are propagating and lobbying for the use of such expensive, impractical methods by making them legally compulsory. Use of barcodes will increase the cost of drugs without any benefit to consumers.”** However, the Department of Commerce appears to be firm on implementing barcoding on secondary packs too. In the last decade, India has exported lakhs of consignments worth billions of dollars to all parts of the world and recalls or rejections on account of quality have been very minimal.*

*We filed a Writ Petition in the Madras High Court in December 2011 seeking intervention in the requirement of implementing barcodes on Pharma secondary and primary packs for exports. We managed to stay the implementation for almost a year. Unfortunately our Writ Petition was dismissed on 21 December 2012. We are informed that barcoding on secondary packs will be implemented from 1<sup>st</sup> January. We have sought an urgent intervention of the Hon'ble Minister of Commerce & Industry.*

*We also organised an emergency meeting of our Members to discuss their issues and concerns regarding the implementation. From the discussions, it appears that neither the industry as a whole, nor the Ministry is fully geared up to implement barcoding at present. We are still hopeful that an amicable solution will be worked out between the industry and Government to ensure that our exports do not suffer. We have requested that an extension of at least six months be provided.*

### **Barcoding for Domestic Retail Packs:**

*The Allahabad High Court in the course of hearing a petition has suggested providing trace and track facilities for domestic sales too, similar to export packs. A Special Task Force was formed by the DCG(I), under the very capable leadership of Shri Hemant Koshia, Commissioner of FDA Gujarat to analyze different ways of combating spurious drugs in India and to study different means for*

drug authentication. The DCG(I) had earlier conducted a countrywide survey, considered the then largest survey undertaken anywhere in the world, to find out the extent of Spurious Drugs in India and published the report in September 2009. The survey showed that the extent of spurious drug in retail Pharmacy was only **0.046%** (11 samples out of 24,136 samples surveyed!) However, as per the directions of the Hon'ble High Court, the Ministry of Health and Family Welfare took up a 'Feasibility Study for Track and Trace of Drugs in India' and selected Wipro Consulting to conduct this study and recommend a drug authentication mechanism by the common man using simple means. Wipro has recently released the report and our experts are studying the requirements and suggestions.

Implementing barcoding would surely be a huge burden on SMEs, as they will have to invest about ₹ 8 to 10 lakhs on barcode machines in a manufacturing line with other miscellaneous costs such as additional manpower to ensure proper coding and others for handling online rejections. In our interactions with the officials at the Ministry of Health, we discussed this scenario, and we realized that they are very much aware of the ground realities and are themselves not too keen on implementing barcoding.

### **33-P direction to States to provide licenses in Proper/Generic names:**

The Central Government recently issued Directions to all State Governments invoking section 33-P of Drugs and Cosmetics Act, 1940 to instruct their State Drug Control authorities to grant/renew licenses of all Single Ingredient Formulations for manufacture for sale or distribution only in proper/generic names. We immediately took up the matter with the Government that the directions are not in accordance with the objective of the Drugs and Cosmetics Act, 1940 which is to ensure availability of safe, standard and efficacious medicines and the Act has nothing to do with brand names. Also the directions are contrary to the provisions of Trade Mark Act and therefore such directions should not be issued invoking Section 33-P. The Government subsequently issued a clarification, that the directive is applicable only for manufacturing licenses issued by the Drugs Licensing Authorities under the provisions of the Drugs and Cosmetics Act and did not extend to export activities and export related documents such as COPP. The clarification was however silent on allowing manufacturers to sell their products under brand names registered under Trade Marks Act.

Meanwhile, the Drugs Controller of Uttarakhand issued letters to manufacturers directing them to sell drugs only under generic name and not to use any brand name on the label of such product. We took up the matter with them to stop issuing such letters as it was beyond their scope to bar manufacturers from using registered brand names. We also met the Health Ministry to request them to immediately direct all the State Drug Control authorities not to issue such directions to sell drugs only under generic name. They understood the gravity of the matter and would be issuing another clarification soon.

### **India's landmark Compulsory License:**

We are very pleased that our stand all along has been justified with the Indian Patent Office granting the country's first Compulsory License to our Member, M/s Natco Pharma Ltd for Sorafenib Tosylate used in treatment for liver and kidney cancer. The Controller General reasoned that the patent holder had not met the reasonable requirement of the public, i.e., it was not affordable and had not 'worked the patent' to a reasonable extent in India. The ruling is fair in the Indian scenario, as there is a massive difference in the prices, as also the conditions imposed on Natco, such as payment of royalty to the patent owner Bayer at 6% of the net sales on a quarterly basis, and also making it obligatory for the company to supply the drug free of cost to at least 600 needy and deserving patients per year.

### **Uniform Code of Pharmaceutical Marketing Practices (UCPMP):**

We met with Shri D S Kalha, Secretary, Department of Pharmaceuticals to discuss the Uniform Code of Pharmaceutical Marketing Practices (UCPMP). Though we pointed out that the Department had not even considered our detailed suggestions, he was of the view that industry should adhere to the same MCI Guidelines as notified – i.e., strictly no free gifts, hospitality etc to medical professionals in any form. He was keen that an Ombudsman be appointed to sit in judgment on alleged violations by the industry. We have now submitted a Marketing Code to the Department of Pharmaceuticals jointly with Indian Pharmaceutical Alliance, that recognizes the role of Pharmaceutical industry in dissemination of knowledge to the medical community and stipulates appropriate disclosures to ensure transparency. This joint code aims at self regulation by establishing a quick redressal system and allows any member of public to log in a complaint.

### **CBDT circular disallowing Gifts to Doctors as Expenses:**

The Central Board of Direct Taxes notified in the beginning of August last year, that the expenses incurred in providing gifts, promotional freebies etc to Doctors by Pharmaceutical and allied health sector industry would not be admissible as expenses and would be taxed. The Circular referred to the Indian Medical Council (Professional Conduct, Etiquette and Ethics) (Amendment) Regulations, 2009 that barred the Medical Practitioners from accepting any gifts, travel facilities, hospitality, cash or monetary grants etc from Pharmaceutical and allied health sector industry. The circular aimed to disallow these from being claimed as expenses by the Pharma industry. Considering the serious implications on Members and the continued development and availability of newer and efficacious medicines to the patients, we represented to the Hon'ble Minister of Finance Shri P Chidambaram requesting that expenses up to a certain amount be allowed as business expenses as also gifts, hospitality, travel facility etc. Also physicians' samples, provided free to them, should be allowed as legitimate expenses. We emphasised that the circular, if implemented, should only be prospective after 31<sup>st</sup> August 2012.

We also met the Revenue Secretary Shri Sumit Bose in October to discuss the implications and the Secretary had agreed to consider our request for prospective implementation of the Circular from 1<sup>st</sup> September 2012.

### **NPPA Internal Guidelines :**

The National Pharmaceutical Pricing Authority (NPPA) published two Internal Guidelines that sought to penalise manufacturers for allegedly 'Overcharging' and selling products 'Without Price Approvals'. It appeared that neither the Dept of Pharma nor the Industry was consulted before releasing the Guidelines on the NPPA website. We immediately sent a submission to the Secretary, Department of Pharmaceuticals requesting that the Internal Guidelines be withheld from implementation. Subsequently, we submitted a detailed representation highlighting the serious irregularities in the Guidelines as NPPA had exceeded its powers and the ensuing ramifications it would have on the industry, a major issue being the penalty of treating entire sales turnover as 'overcharged' amount.

### **New Schedule H1:**

The Health Ministry issued a draft notification to omit 40 drugs from the scope of Schedule H under D&C Rules

and proposed a new Schedule H1 with 91 antibiotics, with special labeling requirements. This was mainly aimed at curbing the rampant misuse of antibiotics for minor ailments to ensure that multi drug resistant bacteria are not created. We agreed with this initiative and only requested for three months time to utilize existing stocks and to make necessary changes in the packing materials such as cartons, labels, aluminium foils, new cylinders for foil printing etc.

### **Some Other Important Meetings with Government Officials:**

This year, we have had regular meetings with key officials to discuss and try to resolve the various industry issues. We organised an interactive meeting with Shri Chaitanya Prasad, Controller General of Patents, Designs & Trademarks to enable Members to be appraised of the current status of the Patent & Trademark Office.

We held interactive meetings with DCG(I) Dr G N Singh on a few occasions. We discussed many issues pertaining to problems in export, import and regulatory activities. He was as always very patient and co-operative and made whole-hearted attempts at resolving the issues.

We also met Dr Jagdish Prasad, Director General of Health Services (DGHS) and discussed various issues such as providing industry representation in DTAB and setting up a Joint Task Force with the Director General in the Chair and 4-5 officials including the DCG(I), the Deputy DC(I)s and industry representatives to meet every three months to discuss industry and policy issues, granting of 'Division' status to CDSCO West Zone to ease the overwhelming burden on the DCG(I)'s office etc. He drew our attention to a major issue: we talk of quality and affordability. Are our medicines efficacious? Do they benefit the patient? Taking a clue from this, we have focused our theme this year on '**Affordable Efficacious Medicines – All Roads Lead to India**'

### **'Affordable Efficacious Medicines – All Roads Lead to India'**

Despite all these odds and challenges, I believe that the Indian Pharma Industry can certainly look forward to exiting times ahead! With the support of the Government and the people, the challenges can be identified and addressed. The Indian Pharmaceutical industry is very dynamic and will take them in its stride, and continue to provide **Affordable Efficacious Medicines** for the common man all over the world to ensure that, as far as

*safe, efficacious and affordable medicines are concerned, All Roads Lead to India!"*

The 51<sup>st</sup> IDMA Annual Publication 2013 was released by the President and other dignitaries on the dais.

The keynote speaker Mr. Amit Backliwal, General Manager, South Asia, IMS Health made a very interesting and informative presentation on "**Growth Opportunities for Indian Pharma**". Mr Backliwal highlighted how substantial urbanization and growth of higher income segments would lead to lifestyle and epidemiological changes, thus putting healthcare systems under severe strain. However, the chronic therapy areas will continue to demonstrate substantial growth and at the same time affordability will determine the overall policy and drug uptake. He said that though Biosimilars have yet to deliver on their promise, specialty and biologics markets will grow at twice the Pharma market rate, Speaking on the Indian scenario, he said that India is a highly diverse market with significant variations in disease prevalence and health infrastructure availability; and companies can gain a better understanding of growth levers based on the demand supply gaps. Predicting the future, he said that Pharmerging markets will drive more than 50% global growth mainly through generics.

Mr. Sriram Shrinivasan, Partner-Life Sciences, Accenture, India made a presentation on "**Prescription for Indian Generic Companies for High Performance in Global Generics**". He said that the Indian Pharma market was growing faster than the Indian GDP and is estimated to reach \$21 bn by 2015. He provided the case study of Teva Pharmaceuticals, one of the leading global generic players and explained how they were driving their significant growth through acquisitions in key global markets and how they were striving to build leadership position across diverse markets.

#### **IDMA Awards:**

Various Awards such as IDMA Quality Excellence Awards 2012, IDMA Best Patent Awards 2011-12, IDMA Research Paper Awards 2012 and IDMA J B Mody Best Student Awards 2011 were presented to the various winners.

#### **IDMA Quality Excellence Awards 2012:**

The Panel of Experts determining this year's **IDMA Quality Excellence Awards 2012** were **Mr. Gidy Asrani, Mr. Kapil Bhargava, Mr. R Raghunandan, Dr. V. Chandrasekharan, Mr J L Sipahimalani,**

**Dr Shailesh Nagarsenkar, Mr Sridharan.** The following units were declared the winners:

#### **(I) Gold Award – 1 no.**

##### **(1) Micro Labs Ltd., Baddi**

*Category : Formulations Units - Companies with Total Annual turnover above ₹ 100 crores*

#### **(II) Silver Awards – 5 nos.**

##### **(1) Troikaa Pharmaceuticals Ltd., Dehradun, Uttarakhand**

*Category : Formulations Unit - Companies with Total Annual turnover above ₹ 100 crores*

##### **(2) Micro Labs Ltd., Ophthalmics Unit, Bangalore**

*Category : Formulations Unit - Companies with Total Annual turnover above ₹ 100 crores*

##### **(3) Micro Labs Ltd., API Unit, Bangalore**

*Category : Bulk Drug Units - Companies with Total Annual turnover above ₹ 100 crores*

##### **(4) Micro Labs Ltd., Goa**

*Category : Formulations Units - Companies with Total Annual turnover above ₹ 100 crores*

##### **(5) ZCL Chemicals Ltd., Ankleshwar**

*Category : Bulk Drug Units - Companies with Total Annual turnover Above ₹ 100 crores*

#### **IDMA Best Patent Awards 2011-12:**

The **IDMA Best Patent Awards 2011-12** Panel of Judges comprised of **Dr Abraham Patani**, Chairman & Past President, **Mr N H Israni**, Past President & Past IPR Sub-Committee Chairman, **Mr Yogin Majmudar**, Vice Chairman, IPR Sub-Committee, **Dr G G Nair**, Convenor (IPR Sub-Committee Chairman), and ex-officio Members, President **Mr Manish Doshi** and Secretary General **Mr. Daara B. Patel**. This year the Panel recommended two Member-companies for **IDMA Outstanding Patent Award 2011-12**. (1) **M/s IPCA Laboratories Ltd., Mumbai for their Six Indian Patents** for Six independent inventions covering novel synthetic processes for APIs (Bulk Drugs) and intermediates and (2) **M/s Sun Pharmaceutical Industries Ltd, Mumbai for their Five Patents** [out of which four are US Patents and one is an E P Patent]. Three of the Patents are for Drug Delivery Systems, One for novel conjugate compounds (API-Anti-tumor product) and One for a Process of synthesis of API. Out of the Five (5) Patents, Four Patents are granted to Sun Pharma Advanced Research Company Ltd. (SPARC) and One Patent is granted to Sun Pharmaceutical Industries Ltd.

### **IDMA Research Paper Awards 2012:**

The best Research Papers published in IDMA Technical and Scientific Journal 'Indian Drugs' during the year 2012 were considered in 5 disciplines as well as the best Review Articles published during the year were also considered for an Award. The Following papers were declared as the Best Research Papers published in their respective disciplines:

#### **Pharmaceutical Chemistry:**

**Paper: Synthesis, Antimalarial Activity and QSAR Studies of Chalcones, N-Benzylidenesulphonamides and Chalcones Sulfonamides**

**Authors: More A.H., Raul S.J. and Mahajan S.S**

Institute: C U Shah College of Pharmacy, S N D T Women's University, Sir Vithaldas Vidya Vihar, Juhu Road, Santacruz (West), Mumbai- 400 049

Volume: 49 (05)

Page no.: 20-34

#### **Natural Products:**

**Paper : Effect of Immunomodulatory Herbal Medicinal Preparations on CD4+ Lymphocyte Count and Total Viral Load in HIV- Infected Individuals**

**Authors : Tharakan S.T., Kuttan G, Kuttan R, Kesavan M., Sr. Austin and Rajagopalan K.**

Institute : Amala Cancer Research Center, Amala Nagar, Trissur- 680555, Kerala

Volume : 49 (07)

Page no. : 42-48

#### **Pharmaceutics:**

**Paper : Development and Characterization of Elementary Osmotic Pump Tablets for Simultaneous Release of Metformin and Glipizide**

**Authors: Dr Peeyush Bhardwaj, Mr Himanshu Chaurasia, Mrs Deepti Chaurasia, Mr Vipin Agarwal, Mr Pranav Upadhyay and Prof. (Dr) R Singh**

Institute : Adarsh Vijendra Institute of Pharmaceutical Science, Babu Vijendra Marg, Gangoh – 247 341, Saharanpur, (U.P.)

**Volume : 49 (11)**

Page no. : 19-29

#### **Pharmaceutical Analysis:**

**Paper: Quantitation of Carvedilol Oxidative Metabolites in Human Plasma using Liquid Chromatography– Tandem Mass Spectrometry**

**Authors : Valarmathy J, Sudha T., Joshua S.L., Senthil Kumar K.L.**

Institute: Department of Pharmaceutical Analysis, The Erode College of Pharmacy, Erode-638112.

Volume: 49 (02)

Page no. : 37-44

No awards were presented this year in the discipline of Pharmacology and for **Review Articles**

### **IDMA J B Mody Best Student Awards 2011:**

This year 14 candidates who stood first in their respective Universities in the final B Pharm Examinations held in 2011 received the IDMA J B Mody Best Student Awards for 2011 as below:

**Mr Kota Seetha Ramaiah**, Annamalai University

**Ms Shilpa Verma**, Banaras Hindu University

**Ms Kumari Sugandha**, Birla Institute of Technology (Deemed University)

**Mr Kulkarni Niteesh Nandkishor**, Dr Babasaheb Ambedkar Marathwada University

**Ms Roopal Jain**, Dr Harisingh Gour Vishwavidyalaya

**Ms Sohini Chakraborti**, Jadavpur University

**Ms Kanchan Khandelwal**, Mohan Lal Sukhadia University

**Ms Ashish Kumari**, Punjabi University

**Ms Sneha G Yadav**, S N D T Women's University

**Mr Gaurang A Patel**, The Maharaja Sayajirao University of Baroda

**Ms Padma Sridevi J**, The Tamil Nadu Dr M G R Medical University

**Ms Jessy John**, University of Kerala

**Ms Chitra A. Varma**, University of Mumbai

**Mr Ashutosh Prakash**, University of Pune

The Secretary General Mr Daara Patel proposed a Vote of Thanks and acknowledged the support of all Members during the year. He thanked President Mr Manish U Doshi, the Speakers - Mr V G Somani, Mr Amit Backliwal and Mr Sriram Shrinivasan and all delegates, invitees and the various Award Winners for their active participation. He also thanked the Members of the Press & Media for their presence and for covering the event.

The Annual Day Celebrations concluded with cocktails and dinner.

# GLIMPSES OF 51<sup>st</sup> ANNUAL DAY CELEBRATIONS



IDMA 51<sup>st</sup> AGM in progress at Hotel-The Lalit, Mumbai on 5<sup>th</sup> January 2013



Audience View – at 51<sup>st</sup> Annual General Meeting (AGM) of IDMA



IDMA 51<sup>st</sup> Annual Day Celebrations formally inaugurated by lighting the traditional lamp at Hotel-The Lalit, Mumbai on 5<sup>th</sup> January 2013. (seen on the image from L to R are Mr Amit Backliwal, General Manager, South Asia, IMS Health, Dr V G Somani, Deputy Drugs Controller, CDSCO, Mr Manish U Doshi, President of IDMA, Shri Sriram Shrinivasan, Partner-Life Sciences, Accenture, India and Mr Daara B Patel, Secretary General, IDMA)



Dr Venugopal G Somani, Deputy Drugs Controller, CDSCO being felicitated with flower bouquet by Mr. Manish Doshi President of IDMA



Shri Shirish Dabhade, Assistant Commissioner, FDA Maharashtra being felicitated by Mr Manish U Doshi, President of IDMA



Mr. Utkarsh Palnitkar, Executive Director of Centrum Capital Limited being welcomed with flower bouquet by Mr Manish U Doshi, President of IDMA



Mr Ranga Iyer, Pharma Consultant being welcomed with flower bouquet by Mr Manish U Doshi, President of IDMA



**IDMA 51<sup>st</sup> Annual Publication 2013 released.** On the dais (L to R) Mr Daara B Patel, Secretary General, Mr Amit Backliwal, General Manager, South Asia, IMS Health, Mr Manish U Doshi, President, Mr Sriram Shrinivasan, Partner-Life Sciences, Accenture, India and Dr Gopakumar G Nair, Past President of IDMA



Mr Manish U Doshi, President of IDMA presenting a memento to Mr Amit Backliwal, General Manager, South Asia, IMS Health



Mr Sriram Shrinivasan, Partner-Life Sciences, Accenture, India being presented a memento by Mr Manish U Doshi, President of IDMA



Mr Manish U Doshi, President, IDMA delivering the welcome address to the audience/participants at the 51<sup>st</sup> Annual Day Celebrations at Hotel-The Lalit, Mumbai on 5<sup>th</sup> Jan 2013. On the dais: Shri Daara B Patel, Mr Amit Backliwal & Mr Sriram Shrinivasan



IDMA Quality Excellence Awards (Gold Award) for 2012 – Category: Formulations Unit – for Companies with annual turnover above ₹ 100 crores - being presented to Micro Labs Ltd., Baddi (Mr S M Mudda accompanied with Mr Prakash Mudda received the Award)



IDMA Quality Excellence Awards (Silver Award) for 2012 – Category: Formulations Unit – Companies with total annual turnover above ₹ 100 crores - being presented to Troikaa Pharmaceuticals Ltd, Uttarakhand. (Mr. Milan R. Patel, Joint Managing Director of Troikaa Pharmaceuticals received the Award)



IDMA Quality Excellence Awards (Silver Award) for 2012 – Category: Formulations Unit – for Companies with total annual turnover of above ₹ 100 crores - being presented to Micro Labs Ltd., Ophthalmic Unit (eye drops unit), Bangalore, (Mr Kiran Sathe, GM - Operations received the Award on behalf of the said unit of Micro Labs)



IDMA Quality Excellence Awards (Silver Award) for 2012 – Category: Bulk Drug Units - for Companies with total annual turnover of above ₹ 100 crores - being presented to Micro Labs Ltd., API Unit, Bangalore. (Mr N B Shenoy, V P – Technical & Operations received the Award on behalf of the said unit of Micro Labs)



IDMA Quality Excellence Awards (Silver Award) for 2012 – Category: Formulations Units - Companies with total annual turnover above ₹100 crores – being presented to M/s. Micro Labs Ltd., Goa (Mr Sanjay Kumar Dasmohapatra, Sr V P – Quality Assurance received the Award on behalf of the said unit of Micro Labs)



IDMA Quality Excellence Awards (Silver Award) for 2012 – Category: Bulk Drug Units-for Companies with total annual turnover above ₹ 100 crores - being presented to ZCL Chemicals Ltd., Ankleshwar. (Mr Piyush Nathwani, VP Operations, accompanied with Mr. Mansukh Kanzaria, DGM - QA received the Award on behalf of ZCL).



*IDMA Outstanding Patent Award 2011-12 being presented to IPCA Laboratories Ltd (Dr Gaurav Sahal, Manager – IPRM accompanied with Mr Rajashekhar Chidurala, Asst Manager IPRM received the Award on behalf of IPCA)*



*Shri Manish Doshi President accompanied by Mr. Gopakumar G Nair, Past President of IDMA presenting the IDMA Outstanding Patent Award 2011-12 to Sun Pharmaceutical Industries Ltd (Dr Eswaran K Iyer, Senior Patent Counsel received the Award for and on behalf of Sun Pharma)*



*Dr V G Somani, DDC, CDSCO accompanied by Mr Manish Doshi presenting the Research Paper Award to Dr Supriya S Mahajan from C U Shah College of Pharmacy, SNDT Women's University, Mumbai*



*Dr Peeyush Bhardwaj from Adarsh Vijendra Institute of Pharmaceutical Science, Gangoh, Saharanpur UP, being presented the Research Paper Award*



*Mr. Manish U Doshi, President accompanied by Mr D B Mody Past President of IDMA presenting the IDMA J B Mody Best University Student's Awards – 2011-12 to Kumari Sugandha, Birla Institute of Technology (Deemed University)*



*Mr. Manish U Doshi, President accompanied by Mr D B Mody, Past President of IDMA presenting the IDMA J B Mody Best University Student's Awards – 2011-12 to Kumari Roopal Jain of Dr Harisingh Gour Vishwavidyalaya*



Mr. Manish U Doshi, President accompanied by Mr D B Mody, Past President of IDMA presenting the IDMA J B Mody Best University Student's Awards – 2011-12 to Ashish Kumari, Punjabi University



Mr. Manish U Doshi, President accompanied by Mr D B Mody, Past President of IDMA presenting the IDMA J B Mody Best University Student's Awards – 2011-12 to Kumari Yadav Sneha Gulab Sushila, SNDT Women's University, Mumbai



Mr. Manish U Doshi, President accompanied by Mr D B Mody, Past President of IDMA presenting the IDMA J B Mody Best University Student's Awards – 2011-12 to Kum Padma Sridevi J, The Tamil Nadu Dr MGR Medical University



Mr. Manish U Doshi, President accompanied by Mr D B Mody, Past President of IDMA presenting the IDMA J B Mody Best University Student's Awards – 2011-12 to Kum Varma Chitra Ajithan Jayashree, University of Mumbai



Mr. Manish U Doshi, President accompanied by Mr D B Mody, Past President of IDMA presenting the IDMA J B Mody Best University Student's Awards – 2011-12 to Ashutosh Prakash, University of Pune



Mr Daara B Patel, Secretary General, IDMA proposing a Vote of Thanks at the 51<sup>st</sup> Annual Day Celebrations at Hotel-The Lalit, Mumbai on 5th Jan 2013